GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CTT Pharmaceutical Holdings Inc (OTCPK:CTTH) » Definitions » ROE %

CTT Pharmaceutical Holdings (CTT Pharmaceutical Holdings) ROE % : -1,640.60% (As of Jun. 2018)


View and export this data going back to . Start your Free Trial

What is CTT Pharmaceutical Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. CTT Pharmaceutical Holdings's annualized net income for the quarter that ended in Jun. 2018 was $-4.36 Mil. CTT Pharmaceutical Holdings's average Total Stockholders Equity over the quarter that ended in Jun. 2018 was $0.27 Mil. Therefore, CTT Pharmaceutical Holdings's annualized ROE % for the quarter that ended in Jun. 2018 was -1,640.60%.

The historical rank and industry rank for CTT Pharmaceutical Holdings's ROE % or its related term are showing as below:

CTTH's ROE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 4.225
* Ranked among companies with meaningful ROE % only.

CTT Pharmaceutical Holdings ROE % Historical Data

The historical data trend for CTT Pharmaceutical Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTT Pharmaceutical Holdings ROE % Chart

CTT Pharmaceutical Holdings Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,418.84 -2,865.71 - 31.15 -158.21

CTT Pharmaceutical Holdings Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Mar17 Jun17 Mar18 Jun18
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -1,640.60

Competitive Comparison of CTT Pharmaceutical Holdings's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, CTT Pharmaceutical Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CTT Pharmaceutical Holdings's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CTT Pharmaceutical Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where CTT Pharmaceutical Holdings's ROE % falls into.



CTT Pharmaceutical Holdings ROE % Calculation

CTT Pharmaceutical Holdings's annualized ROE % for the fiscal year that ended in Dec. 2015 is calculated as

ROE %=Net Income (A: Dec. 2015 )/( (Total Stockholders Equity (A: Dec. 2014 )+Total Stockholders Equity (A: Dec. 2015 ))/ count )
=-1.446/( (1.493+0.335)/ 2 )
=-1.446/0.914
=-158.21 %

CTT Pharmaceutical Holdings's annualized ROE % for the quarter that ended in Jun. 2018 is calculated as

ROE %=Net Income (Q: Jun. 2018 )/( (Total Stockholders Equity (Q: Mar. 2018 )+Total Stockholders Equity (Q: Jun. 2018 ))/ count )
=-4.364/( (-0.127+0.659)/ 2 )
=-4.364/0.266
=-1,640.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2018) net income data. ROE % is displayed in the 30-year financial page.


CTT Pharmaceutical Holdings  (OTCPK:CTTH) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2018 )
=Net Income/Total Stockholders Equity
=-4.364/0.266
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-4.364 / 0)*(0 / 0.576)*(0.576 / 0.266)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*2.1654
=ROA %*Equity Multiplier
=N/A %*2.1654
=-1,640.60 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2018 )
=Net Income/Total Stockholders Equity
=-4.364/0.266
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-4.364 / -4.364) * (-4.364 / -4.36) * (-4.36 / 0) * (0 / 0.576) * (0.576 / 0.266)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0009 * N/A % * 0 * 2.1654
=-1,640.60 %

Note: The net income data used here is four times the quarterly (Jun. 2018) net income data. The Revenue data used here is four times the quarterly (Jun. 2018) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


CTT Pharmaceutical Holdings ROE % Related Terms

Thank you for viewing the detailed overview of CTT Pharmaceutical Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


CTT Pharmaceutical Holdings (CTT Pharmaceutical Holdings) Business Description

Traded in Other Exchanges
N/A
Address
1100 – 1111 Melville Street, Vancouver, BC, CAN, V6E 3V6
CTT Pharmaceutical Holdings Inc is a development stage company specializing in drug delivery systems technology within the pharmaceutical industry. It focuses on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The thin wafers are infused with both natural and synthetic cannabis extracts to deliver treatment as an alternative to smoking and ingestion. Its products include Medwafe, Cannawafe, Vetwafe, and others.
Executives
Albert C Zapanta director PO BOX 2020, SPRINGDALE AR 72765
William Thomson director 390 BAY ST, SUITE 1102, TORONTO ONTARIO A6 M5H 2Y2